BIOMAT Database Logo BIOMAT Database Logo

The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. 1990

N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Department of Medicine, New England Medical Center, Boston, MA 02111.

A nationwide survey to monitor the susceptibility of the Bacteroides fragilis group, which began in 1981, was continued during 1987. In addition to the eleven drugs evaluated in 1986, sulbactam, a potent beta-lactamase inhibitor, was tested alone and in combination with ampicillin and cefoperazone. Imipenem, ampicillin/sulbactam, cefoperazone/sulbactam, and ticarcillin/clavulanic acid were the most active newer drugs tested, with less than 1% resistance rates. Chloramphenicol, metronidazole and clindamycin also had excellent activity with resistance rates of 0%, 0%, and 3% respectively. Resistance rates to cefoxitin remained stable at 8%. Ceftizoxime and cefotetan had resistance rates of 26% and 29%, respectively. Rates of resistance varied among different institutions and between the various species.

UI MeSH Term Description Entries
D007769 Lactams Cyclic AMIDES formed from aminocarboxylic acids by the elimination of water. Lactims are the enol forms of lactams. Lactam,Lactim,Lactims
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001439 Bacteroides A genus of gram-negative, anaerobic, rod-shaped bacteria. Its organisms are normal inhabitants of the oral, respiratory, intestinal, and urogenital cavities of humans, animals, and insects. Some species may be pathogenic.
D001441 Bacteroides fragilis Gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections.
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.

Related Publications

N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.
January 1992, Clinical therapeutics,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Susceptibility of the Bacteroides fragilis group in the United States in 1981.
April 1983, Antimicrobial agents and chemotherapy,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.
November 1985, Antimicrobial agents and chemotherapy,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe.
June 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Survey of Bacteroides fragilis group susceptibility patterns in Canada.
February 1992, Antimicrobial agents and chemotherapy,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Survey of Bacteroides fragilis group susceptibility patterns in Brazil.
March 1997, International journal of antimicrobial agents,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation.
May 1988, Antimicrobial agents and chemotherapy,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Antimicrobial resistance patterns of Bacteroides fragilis group organisms in Korea.
December 1998, Yonsei medical journal,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
[Antimicrobial Susceptibility of Bacteroides fragilis and Bacteroides thetaiotaomicron]
November 1998, Rinsho Biseibutsu Jinsoku Shindan Kenkyukai shi = JARMAM : Journal of the Association for Rapid Method and Automation in Microbiology,
N A Cornick, and G J Cuchural, and D R Snydman, and N V Jacobus, and P Iannini, and G Hill, and T Cleary, and J P O'Keefe, and C Pierson, and S M Finegold
Variation in susceptibility patterns of species within the Bacteroides fragilis group.
April 1980, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!